Drug intelligence / Profile preview

AMP-601

Development stage: Preclinical
Lead developer: Amplifica Holdings Group
Modality: Recombinant Proteins and Enzymes

Overview

AMP-601 is a proprietary, early-stage biopharmaceutical compound being developed by Amplifica for the treatment of hair loss, specifically androgenetic alopecia and other forms of alopecia. The active agent in AMP-601 is SCUBE3 (Signal peptide-CUB-EGF-like domain-containing protein 3), a multifunctional signaling protein. Preclinical research has shown that SCUBE3 can drive the growth of normal hair follicles and potentially stimulate new hair growth when applied to skin. The mechanism involves stimulating molecular pathways that activate dormant or miniaturized hair follicles, promoting their transition into active growth phases. AMP-601 is currently in preclinical development and has not yet entered human clinical trials[4][7].

Other names: SCUBE3SCUBE-3SCUBE 3

Targets

SCUBE3

Beyond the preview

Go deeper on AMP-601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMP-601.

Explore the full profile